BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scarante FF, Ribeiro MA, Almeida-Santos AF, Guimarães FS, Campos AC. Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders. Front Pharmacol 2020;11:618065. [PMID: 33613284 DOI: 10.3389/fphar.2020.618065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Franzen JM, Werle I, Vanz F, de Oliveira BB, Martins Nascimento LM, Guimarães FS, Bertoglio LJ. Cannabidiol attenuates fear memory expression in female rats via hippocampal 5-HT(1A) but not CB1 or CB2 receptors. Neuropharmacology 2023;223:109316. [PMID: 36334768 DOI: 10.1016/j.neuropharm.2022.109316] [Reference Citation Analysis]
2 Liu L, Liu J, Zhao M, Cai M, Lei F, Zeng X, Zhu B. A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.969883] [Reference Citation Analysis]
3 de Almeida V, Seabra G, Reis-de-Oliveira G, Zuccoli GS, Rumin P, Fioramonte M, Smith BJ, Zuardi AW, Hallak JEC, Campos AC, Crippa JA, Martins-de-Souza D. Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 35622101 DOI: 10.1007/s00406-022-01425-5] [Reference Citation Analysis]
4 Molina-Holgado E, Esteban PF, Arevalo-Martin Á, Moreno-Luna R, Molina-Holgado F, Garcia-Ovejero D. Endocannabinoid signaling in oligodendroglia. Glia 2022. [PMID: 35411970 DOI: 10.1002/glia.24180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kibret BG, Ishiguro H, Horiuchi Y, Onaivi ES. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. Int J Mol Sci 2022;23:975. [PMID: 35055161 DOI: 10.3390/ijms23020975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Harry GJ. Cannabinoids. Advances in Neurotoxicology 2022. [DOI: 10.1016/bs.ant.2022.06.001] [Reference Citation Analysis]
7 Tizabi Y, Getachew B, Copeland RL, Moratalla R, Patricio F, Limón ID, Del-bel E, Aschner M. Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia. Handbook of Neurotoxicity 2022. [DOI: 10.1007/978-3-031-15080-7_218] [Reference Citation Analysis]
8 R.b. Weiss S, Delrahim Howlett K. Cannabidiol: Overview, Complexities, and Opportunities for Behavioral Health. Cannabis in Psychiatric Practice 2022. [DOI: 10.1007/978-3-031-04874-6_3] [Reference Citation Analysis]
9 Landucci E, Mazzantini C, Lana D, Davolio PL, Giovannini MG, Pellegrini-Giampietro DE. Neuroprotective Effects of Cannabidiol but Not Δ9-Tetrahydrocannabinol in Rat Hippocampal Slices Exposed to Oxygen-Glucose Deprivation: Studies with Cannabis Extracts and Selected Cannabinoids. Int J Mol Sci 2021;22:9773. [PMID: 34575932 DOI: 10.3390/ijms22189773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Tizabi Y, Getachew B, Copeland RL, Moratalla R, Patricio F, Limón ID, Del Bel E, Aschner M. Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia. Handbook of Neurotoxicity 2021. [DOI: 10.1007/978-3-030-71519-9_218-1] [Reference Citation Analysis]